ASML
ASML Holding N.V.
ASML has the edge over OSCR overall, supported by lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
ASML Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Strong | |
| Strong |
ASML's profitability, cash flow and balance sheet are currently strong. There isn't enough data to rate its revenue.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ASML PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 35x | $1,375 | -8.2% |
| Current | 39x | $1,497 | — |
| Fair | 43x | $1,684 | +13% |
| Expensive | 56x | $2,177 | +45% |
Historical ranges are pointers, not guarantees.
ASML's PE is 39x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ASML in the historical PE scenario, which offers more potential upside but is not a forecast.
ASML Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ASML, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ASML Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $38.88 | +44% |
| Q2 2026 | $30.61 | +15% |
| Q3 2025 | $26.91 | +38% |
| Q2 2025 | $26.68 | +40% |
| Q1 2025 | $24.60 | +22% |
| Q4 2024 | $21.42 | -2.9% |
| Q3 2024 | $19.46 | -8.4% |
| Q2 2024 | $19.11 | -7.5% |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 58% for ASML versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ASML Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13B | +55% |
| Q2 2026 | $10.4B | +21% |
| Q1 2026 | $9.7B | +13% |
| Q4 2025 | $10.8B | +4.9% |
| Q3 2025 | $8.3B | +0.7% |
| Q3 2025 | $8.3B | +0.7% |
| Q2 2025 | $8.5B | +23% |
| Q1 2025 | $8.6B | +46% |
ASML's revenue has grown year over year for four quarters in a row: $13B last quarter, up 55% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 44% | +12 points |
| Q2 2026 | 37% | +4.2 points |
| Q1 2026 | 36% | +1.4 points |
| Q4 2025 | 35% | -0.1 points |
| Q3 2025 | 33% | -3.4 points |
| Q3 2025 | 33% | +0.2 points |
| Q2 2025 | 35% | +5.3 points |
| Q1 2025 | 35% | +9.1 points |
ASML has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ASML on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ASML Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12.6B | +4571% |
| Q2 2026 | $1.6B | +292% |
| Q1 2026 | -$2.9B | -$2.4B |
| Q4 2025 | $12.2B | +24% |
| Q3 2025 | $270.7M | -54% |
| Q3 2025 | $270.7M | -54% |
| Q2 2025 | $397.4M | -10% |
| Q1 2025 | -$527.8M | +$223M |
ASML generated $23.5B in free cash flow over the past year, more than ten times what it generated the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ASML on cash flow, with more consistent year-over-year improvement.
ASML Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -1.4M shares |
| 1 year | -1.1% | -4.1M shares |
| 3 years | -2.6% | -10.3M shares |
| 5 years | -5.3% | -21.5M shares |
| Available history | -8.6% | -36.2M shares |
ASML has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.5B |
| Q2 2026 | $1.2B |
| Q1 2026 | $1.1B |
| Q4 2025 | $1.9B |
| Q3 2025 | $191.3M |
| Q3 2025 | $191.3M |
| Q2 2025 | $1.6B |
| Q1 2025 | $2.9B |
ASML spent $8.7B buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ASML Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.4x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.8x | Net Cash |
| Q3 2024 | -0.0x | Net Cash |
| Q2 2024 | -0.0x | Net Cash |
ASML has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ASML on leverage, with a lower net debt burden relative to earnings.
ASML Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.5 | Neutral |
| Stochastic | 16.3 | Oversold |
ASML's weekly RSI is 44 (neutral) and its Stochastic is 16 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ASML PE vs Technology Sector
| Metric | ASML | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 28x | 38% above |
| PE % | 30 | 35 | 5 pts below |
ASML is trading at 39x earnings, a 38% premium to the Technology sector's median of 28x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ASML on valuation relative to its sector.
ASML Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,636.6 | 8.5% below |
| 20 week MA | $1,696.6 | 12% below |
| 50 week MA | $1,531.1 | 2.2% below |
| 100 week MA | $1,160.1 | 29% above |
| 200 week MA | $964.4 | 55% above |
ASML has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 55% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ASML on trend strength, trading above more of its moving averages.
ASML Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.7 | $483.1 | +63% |
| 2021 | $483.1 | $801.4 | +66% |
| 2022 | $801.4 | $551.4 | -31% |
| 2023 | $551.4 | $756.9 | +37% |
| 2024 | $756.9 | $713.6 | -5.7% |
| 2025 | $713.6 | $1,072.8 | +50% |
| 2026 YTD | $1,072.8 | $1,497.1 | +40% |
ASML has finished higher in four of the last six years, three of them by more than 50%. It's up 40% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ASML on returns for 2026, with the stronger performance.